Novo Nordisk, a competitor to Eli Lilly, has already sought FDA approval for an oral semaglutide pill, its oral GLP-1 pill, and is expected to receive a decision by the end of this year
However, in the AWARD 7 trial, a dedicated 52-week trial of dulaglutide in patients with diabetic kidney disease, stage 3-4, the decline with time was significantly reduced compared with insulin glargine [29]
Comparing Costs of New Weight Loss Medications The cost of new weight loss medications can be a significant barrier for many individuals
Catalogued internally as GLP-3R and assigned CAS number 2381089-83-2, it represents a next-generation investigational tool in metabolic research, extending beyond the dual GLP-1R/GIPR co-agonism seen in earlier peptide scaffolds
doi: 10.1001/jamanetworkopen.2023.50408